SPV106
SPV106 has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 18, 2025: “Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction”.
At a glance
The findings reach mice, none yet in people. 1 lab in 2 countries.
None of its findings points the other way.
- 1 lab in 2 countries
- Animals1
What did studies of SPV106 find?
4Studies of SPV106 measured 4 outcomes, among them cardiac function, calcification of the aortic valve and calcific lesions.
Cardiac function
upin mice1
1 study
Cardiac function
upin mice1
SPV106 improves cardiac function in Vitamin-D-induced calcification model.
“positively preserved the valve motion compromised by calcification and the overall cardiac function.”
Animalsin Vitamin-D-induced calcification model
Signal transduction and targeted therapy
Calcification of the aortic valve
downin mice1
1 study
Calcification of the aortic valve
downin mice1
SPV106 decreases calcification of the aortic valve in Vitamin-D-induced calcification model.
“In vivo treatment with SPV106 reduced calcification of the valve induced by administering Vitamin-D”
Animalsin Vitamin-D-induced calcification model
Signal transduction and targeted therapy
Calcific lesions
downin human cells1
1 study
Calcific lesions
downin human cells1
SPV106 prevents calcific lesions in human cells (ex vivo model of aortic valve calcification).
“The treatment also prevented the accumulation of calcific lesions in an ex vivo model of aortic valve calcification.”
Cellsex vivo model of aortic valve calcification
Signal transduction and targeted therapy
NOTCH1
upin human cells1
1 study
NOTCH1
upin human cells1
SPV106 increases NOTCH1 in cultured human VICs.
“In human VICs, SPV106 restored Histone acetylation marks, modified general chromatin accessibility and upregulated expression of Notch1”
Cellsin cultured human VICs
Signal transduction and targeted therapy